Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.

Loading...
Thumbnail Image
Authors
Mowat, C.
Arnott, I.
Cahill, A.
Smith, M.
Ahmad, Tariq
Subramanian, S.
Travis, S.
Morris, J.
Hamlin, J.
Dhar, A.
Journal
Lancet Gastroenterology & Hepatology
Type
Journal Article
Randomized Controlled Trial
Publisher
Elsevier
Rights
Archived with thanks to The lancet. Gastroenterology & hepatology.This article is available as Open Access under Creative Commons License CC-BY.
Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease.
Citation
Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. 2016, 1 (4):273-282 Lancet Gastroenterol Hepatol
Note
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.